Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2- oncoprotein expression in adenocarcinoma of the lung

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 2, 1998, Pages 155-160

  Nemunaitis, John ^a,b,d   Klemow, Steven ^a   Tong, Alex ^b   Courtney, Alice ^b   Johnston, Walter ^c   Mack, Michael ^d   Taylor, Wayne ^d   Solano, Max ^f   Stone, Marvin ^f   Mallams, John ^e   Mues, Gabriele ^e  

^a TEXAS ONCOLOGY   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c Prescob Consultants   (United States)

^d MEDICAL CITY DALLAS HOSPITAL   (United States)

^e BAYLOR RESEARCH INSTITUTE   (United States)

^f Collins Building ^*

Author keywords

K ras; Non small cell lung cancer

Indexed keywords

ONCOPROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; DIAGNOSTIC VALUE; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE C ERB; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; FEMALE; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0031922727     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199804000-00013     Document Type: Article

References (50)

1. Yesner R. Pathogenesis and pathology. Clin Chest Med 1993;14:17-30.
2. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 1995;13:1221-30.
3. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992;327:1434-1441.
4. Strauss GM, Kwiatkowski DJ, Harpole DH, et al. Molecular and pathologic markers in stage 1 non-small cell carcinoma of the lung. J Clin Oncol 1995;13:1-18.
5. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980;65:25-32.
6. O'Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986;4:1604-14.
7. Sorensen JB, Badsberg JH, Olsen F. Prognostic factors in inoperable adenocarcinoma of the lung: a multivariate regression analysis in 259 patients. Cancer Res 1989;49:5748-54.
8. Albain KS, Crowley JJ, Lebland M, et al. Survival determinants in extensive stage non-small cell lung cancer. The Southwest Oncology Group Experience. J Clin Oncol 1991;9:1618-26.
9. Shinkay T, Eguchi K, Sasaki Y, et al. A prognostic-factor index in advanced non-small cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol 1992;30:1-6.
10. Gail M, Eagan RT, Feld R, et al. Prognostic factors in patients with resected stage I NSCLC: a report from the Lung Cancer Study Group. Cancer 1984;54:1802-13.
11. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-Ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990;323:561-5.
12. Mitsudomi T, Stenberg SM, Oie H, et al. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991;51:4999-5002.
13. Harada M, Dosaka-Akita H, Miyamoto H, et al. Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer 1992;69:72-7.
14. Kern J, Slebos R, Top B, et al. C-erb B-2 expression and codon 12 K-Ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 1994;93:516-20.
15. new expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990;50:5184-91.
16. Tateishi M, Ishida T, Mitsudomi T, et al. Prognostic value of C-erb B-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 1991;27:1372-5.
17. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small cell lung carcinoma. N Engl J Med 1993;329:690-4.
18. Carbone DP, Mistudomi T, Rusch V, et al. p53 protein over-expression, but no gene mutation is predictive of significantly shortened survival in resected non-small cell cancer patients [abstract]. Proc Am Soc Clin Oncol 1993;12:334.
19. Quinlan DC, Davidson AG, Summers CL, et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992;52:4828-31.
20. Mitsudomi T, Oyama T, Kusano T, et al. Mutation of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J Natl Cancer Inst 1993;85:2018-23.
21. Horio Y, Takahashi T, Kurosishi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993;53:1-4.
22. Xu HJ, Quinlan DC, Davidson AG, et al. Altered retinoblastoma protein expression and prognosis in early stage non-small cell lung carcinoma. J Natl Cancer Inst 1994;86:695-9.
23. Marx J. Forging a path to the nucleus. Science 1993;260:1588-90.
24. Rodenhuis S. Ras and human tumors. Semin Cancer Biol 1992;3:241-7.
25. Kashii T, Muzushima Y, Monno S, et al. Gene analysis of K-, H-Ras, p53 and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction single strand conformation polymorphism method. J Cancer Res Clin Oncol 1994;120:143-8.
26. Slebos RJC, Hruban RN, Dalesio O, et al. K-Ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 1991;83:1024-7.
27. Rosell R, Li S, Skacel Z, et al. Prognostic impact of mutated K-Ras gene in surgically resected non-small cell lung cancer patients. Oncogene 1993;8:2407-12.
28. Miyamoto H, Harada M, Isobe H, et al. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer. Cancer Res 1991;51:6346-50.
29. Hill SA, Wilson S, Chambers AF. Clonal heterogeneity, experimental metastatic ability and p21 expression in H-ras transformed NIH 3T3 cells. J Natl Cancer Inst 1988;80:484-7.
30. Chambers AF, Denhardt GH, Wilson SM. Ras-transformed NIH 3T3 cell lines, selected for metastatic ability in chick embryos have increased proportions of p21-expressing cells and are metastatic in nude mice. Invasion Metastasis 1990;10:225-30.
31. Harada M, Dosak-Akita H, Miyamot H, et al. Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer 1992;69:72-7.
32. Stern DE, Heffeman PA, Weinberg RA. A product of the new proto-oncogene is a receptor-like protein associated with tyrosine kinase activity p185. Mol Cell Biol 1986;6:1729-40.
33. Prost S, Le MG, Dasy SD, et al. Association of c-erb B-2-gene amplification with poor prognosis in non-inflammatory breast carcinoma but not in carcinomas of the inflammatory type. Int J Cancer 1994;58:763-8.
34. Natali PG, Nocotra MR, Bigotti A, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990;45:457-61.
35. Tong AW, Lee JC, Stone MJ. Discrimination of human small cell and non-small cell lung tumors by a panel of monoclonal antibodies. J Natl Cancer Inst 1986;77:1023-33.
36. Lee ET. Statistical methods for survival data analysis, 2nd ed. Philadelphia: Wiley. 1992:116-7.
37. Cox DR, Hingley DV. Lagrange multiplier chi-square. Theoretical Statistics 1974:350-5.
38. Sklar MD. Increased resistance to cis-diamminedichloroplatinum (II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res 1988;48:793-7.
39. Wishart GC, Plumb JA, Spandidos DA, et al. H-ras transfection in mink lung epithelial cells may induce "atypical multidrug resistance." Eur J Cancer 1991;27:673-5.
40. McKenna WG, Weiss MC, Bakanauskas VJ, et al. The role of H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biophys 1990;18:849-59.
41. Chambers AF, Tuck AB. Ras-responsive genes and tumor metastasis. Crit Rev Oncog 1993;4:95-114.
42. Tanaka T, Seeger RC, Tanabe M, et al. Prognostic prediction in neuroblastomas: clinical significance of combined analysis for Ha-ras p21 expression and n-myc gene amplification. Cancer Detect Prev 1994;18:283-9.
43. Isobe T, Hiyama K, Yoshida Y, et al. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. Jpn J Cancer Res 1994;85:1240-6.
44. Sabbatini ARM, Basolo F, Valentini P, et al. Induction of multi-drug resistance (MDR) by transfection of MCF-10A cell line with c-Ha-ras and c-erb B-2 oncogenes. Int J Cancer 1994;59:208-11.
45. Nimi S, Nakagawa K, Yokota J, et al. Resistance to anticancer drugs in NIH 3T3 cells transfected with c-myc and/or c-H-ras genes. Br J Cancer 1991;63:237-41.
46. Sabet MK, Funato T, Tone T, et al. Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res Dev 1992;2:3-15.
47. Kung HF, Smith MR, Bekesi E, et al. Reversal of transformed phenotype by monoclonal antibodies against Ha-ras p21 proteins. Exp Cell Res 1986;162:363-71.
48. Leitzel K, Teamoto Y, Konrad K, et al. Elevated serum c-erb B-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13(5):1129-35.
49. Zhand Y, Mukhopadhyay T, Donehower LA, et al. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 1993;4:451-60.
50. Mao L, Hruban RH, Boyle JO, et al. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994;54:1634-7.